Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Fortress Biotech Inc

Company price
1.7 USD -0.01 ( 0.58%)
Last update at 2026-11-17T15:09:00Z
VOLUME
71390
Market Cap
71.81M

Momentum Score

…

Fortress Biotech, Inc., a biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products. The company markets dermatology products, including Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe recalcitrant nodular acne; Amzeeq, a topical formulation of minocycline for inflammatory lesions of non-nodular moderate to severe acne vulgaris; Zilxi for inflammatory lesions of rosacea; Exelderm, an antifungal cream and solution for topical use; Targadox, an oral doxycycline drug for therapy for severe acne; and Luxamend, a water-based emulsion to provide a moist healing environment for superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, sunburns, and radiation dermatitis. It also develops intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for Menkes disease; UNLOXCYT for metastatic cutaneous squamous cell carcinoma; Olafertinib for EGFR mutation-positive NSCLC; CAEL-101, a monoclonal antibody for amyloid light chain amyloidosis; and Triplex, a cytomegalovirus vaccine. In addition, the company's early-stage product candidates include Dotinurad for gout; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma and anaplastic astrocytoma; MB-106 for B-cell non-hodgkin lymphoma; AJ201, an androgen receptor degradation enhancer; and BAER-101, a positive allosteric modulator. Further, its preclinical product candidates comprise AAV-ATP7A and AVTS-001 gene therapies; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.64
Low
1.71
High
52 Week Price Range
1.60
Low
4.53
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Fortress Biotech, Inc. is a biopharmaceutical company that acquires, develops and seeks to commercialize prescription drugs and biologics through a portfolio of subsidiaries and strategic partnerships. Long-term growth may be driven by clinical progress and regulatory approvals across its pipeline, licensing or partnership deals, and commercialization of any approved products, which could support value realization across its diversified asset base.
Key risks include clinical and regulatory setbacks, substantial financing requirements that could lead to dilution, and operational complexity from managing multiple subsidiary programs.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
1.71
Dividend Yield
-
Revenue TTM
63.26M
Revenue Per Share
2.27
Gross Profit TTM
30.44M
Debt / Equity
1.49
ROE
-108.74%
Net Debt
-5.08M
ROCE
-18.28%
Diluted EPS TTM
-0.07

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -33.53M -120.54M -153.63M -213.46M -164.35M
Minority interest 39.73M 74.86M 104.31M 127.34M -100.12M
Net income 6.82M -46.00M -60.64M -213.91M -164.83M
Selling general administrative 96.40M 87.73M 99.71M 113.66M 86.84M
Gross profit 42.34M 36.80M 55.62M 44.97M 36.71M
Reconciled depreciation 4.66M 4.46M 8.96M 9.35M 6.79M
Ebit -24.83M -108.95M -139.24M -202.26M -179.00M
Ebitda -20.16M -104.49M -131.17M -200.86M -178.35M
Depreciation and amortization 4.66M 4.46M 8.07M 1.40M 0.65M
Non operating income net other - - - - 24.19M
Operating income -70.22M -110.38M -139.24M -202.26M -179.00M
Other operating expenses 133.48M 168.05M 223.75M 278.00M 247.79M
Interest expense 8.71M 9.93M 11.91M 13.64M 15.31M
Tax provision -0.62M 0.31M 0.59M 0.45M 0.47M
Interest income 2.48M 2.68M 2.98M 1.40M 0.65M
Net interest income -7.62M -10.84M -15.02M -12.24M -14.66M
Non recurring - - - - 15.62M
Income tax expense -0.62M 0.31M 0.52M 0.45M 0.47M
Total revenue 63.26M 57.67M 84.51M 75.74M 68.79M
Total operating expenses 112.56M 147.18M 194.87M 247.23M 215.71M
Cost of revenue 20.92M 20.88M 28.89M 30.77M 32.08M
Total other income expense net 36.69M -10.16M -14.39M -11.20M 14.65M
Net income from continuing ops -32.91M -120.86M -182.62M -213.91M -164.83M
Net income applicable to common shares - - - - -64.70M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 185.55M 144.22M 167.53M 294.30M 396.50M
Intangible assets 27.61M 31.86M 20.29M 27.20M 12.55M
Other current assets 5.05M 8.28M 10.50M 9.66M 7.07M
Total liab 123.36M 145.87M 165.94M 244.28M 170.63M
Total stockholder equity 49.87M 22.74M 22.54M 41.72M 108.67M
Other current liab 33.02M 35.58M 39.80M 16.91M 0.34M
Common stock 0.03M 0.03M 0.01M 0.11M 0.10M
Capital stock 0.03M 0.03M 0.02M 0.11M 0.10M
Retained earnings -734.05M -740.87M -694.87M -634.23M -547.46M
Other liab - - - - 2.03M
Other assets - - - - 3.42M
Cash 79.38M 57.26M 80.93M 178.27M 305.74M
Total current liabilities 49.74M 71.40M 84.91M 127.72M 101.04M
Current deferred revenue - - 0.84M 0.73M 2.61M
Net debt -5.08M 18.70M 7.67M -50.92M -230.77M
Short term debt 2.13M 3.25M 9.45M 12.63M 7.43M
Short long term debt - 0.62M 3.00M 10.18M 5.32M
Short long term debt total 74.30M 75.96M 88.59M 127.34M 74.98M
Other stockholder equity 783.89M 763.57M 717.40M 675.84M 656.03M
Property plant equipment - - - - 34.07M
Total current assets 123.84M 90.37M 117.02M 230.43M 346.46M
Long term investments 17.66M 2.58M - - 0.00M
Net tangible assets - - - - 96.12M
Net receivables 29.94M 10.40M 15.39M 28.35M 23.79M
Long term debt 59.50M 57.96M 60.86M 93.14M 46.56M
Inventory 9.62M 14.43M 10.21M 14.16M 9.86M
Accounts payable 14.24M 31.64M 34.81M 97.45M 90.66M
Noncontrolling interest in consolidated entity - - - - 117.20M
Accumulated other comprehensive income - - -0.00M - -
Common stock total equity - - - - 0.10M
Preferred stock total equity - - - - 0.00M
Retained earnings total equity - - - - -547.46M
Non currrent assets other 1.62M 3.32M 4.28M 3.66M 3.42M
Non current assets total 61.71M 53.85M 50.50M 63.87M 50.04M
Capital lease obligations 14.80M 17.37M 20.80M 24.02M 23.09M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -15.00M -2.43M -22.93M 56.86M
Change to liabilities - - - - 46.35M
Total cashflows from investing activities 10.12M -15.00M - - 40.51M
Net borrowings -5.64M -7.33M - - -15.03M
Total cash from financing activities 77.44M 70.64M 32.74M 75.32M 148.99M
Change to operating activities - - - - -2.20M
Net income -32.91M -120.86M -60.64M -213.91M -164.83M
Change in cash 21.79M -24.55M -97.34M -127.01M 72.97M
Begin period cash flow 58.81M 83.36M 178.27M 307.96M 235.00M
End period cash flow 80.60M 58.81M 80.93M 180.95M 307.96M
Total cash from operating activities -65.78M -80.19M -128.22M -179.40M -116.54M
Issuance of capital stock 81.68M 82.84M 70.97M 42.97M 172.23M
Depreciation 4.66M 4.46M 8.07M 9.35M 6.79M
Other cashflows from investing activities 1.17M - - - -11.78M
Dividends paid 0.66M 4.71M 8.77M 8.78M 8.78M
Change to inventory 4.81M -4.22M 3.95M 1.74M -8.46M
Change to account receivables -19.33M 4.47M 12.52M -5.38M 0.77M
Sale purchase of stock -0.27M 0.00M -0.40M -1.20M 24.28M
Other cashflows from financing activities -0.62M -0.16M -1.09M 47.73M -5.40M
Change to netincome - - - - 20.32M
Capital expenditures 0.00M 15.00M 8.10M 3.06M 16.35M
Change receivables - - - - 0.83M
Cash flows other operating - - - - -17.29M
Cash and cash equivalents changes - - - - 72.97M
Change in working capital -25.10M -8.13M -12.52M -0.71M 36.37M
Stock based compensation 28.74M 32.62M 17.03M 22.99M 19.49M
Other non cash items -41.17M 11.71M -88.05M 2.89M 24.43M
Free cash flow -65.78M -95.19M -136.32M -182.46M -132.89M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
FBIO
Fortress Biotech Inc
-0.01
0.58%
1.70 - 3.73 1.14 1.45 1.06 -0.29
NVO
Novo Nordisk A/S
-1.21
2.90%
40.40 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
-6.15
1.14%
531.64 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc
4.70
0.49%
957.10 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Fortress Biotech Inc

Fortress Biotech, Inc., a biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products. The company markets dermatology products, including Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe recalcitrant nodular acne; Amzeeq, a topical formulation of minocycline for inflammatory lesions of non-nodular moderate to severe acne vulgaris; Zilxi for inflammatory lesions of rosacea; Exelderm, an antifungal cream and solution for topical use; Targadox, an oral doxycycline drug for therapy for severe acne; and Luxamend, a water-based emulsion to provide a moist healing environment for superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, sunburns, and radiation dermatitis. It also develops intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for Menkes disease; UNLOXCYT for metastatic cutaneous squamous cell carcinoma; Olafertinib for EGFR mutation-positive NSCLC; CAEL-101, a monoclonal antibody for amyloid light chain amyloidosis; and Triplex, a cytomegalovirus vaccine. In addition, the company's early-stage product candidates include Dotinurad for gout; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma and anaplastic astrocytoma; MB-106 for B-cell non-hodgkin lymphoma; AJ201, an androgen receptor degradation enhancer; and BAER-101, a positive allosteric modulator. Further, its preclinical product candidates comprise AAV-ATP7A and AVTS-001 gene therapies; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

1111 Kane Concourse, Bay Harbor Islands, FL, United States, 33154

781 652 4500

78

Name Title Year Born
Dr. Lindsay Allan Rosenwald Exec. Chairman, Pres & CEO 1955
Mr. Michael S. Weiss Esq. Vice Chairman & Exec. Vice Chairman of Strategic Devel. 1966
Dr. George C. Avgerinos Sr. VP of Biologics Operations 1954
Ms. Robyn M. Hunter Exec. Officer 1962
Mr. David Jin CFO & Head of Corp. Devel. 1990
Mr. Samuel Berry Gen. Counsel & Corp. Sec. NA
Dr. Thomas F. Schaible Project Leader of Inflammatory Bowel Disease NA
Dr. Lindsay Allan Rosenwald Executive Chairman, President & CEO 1955
Mr. David Jin CFO & Head of Corporate Development 1991
Mr. Michael S. Weiss Esq. Executive Vice Chairman of Strategic Development & Director 1966

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…